Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts, Gerald F.; Gidding, Samuel S.; Wierzbicki, Anthony S.; Tóth, Peter P.; Alonso, Rodrigo; Brown, W. Virgil; Bruckert, Éric; Defesche, Joep C.; Lin, Khoo Kah; Livingston, Michael; Mata, Pedro; Parhofer, Klaus G.; Raal, Frederick J.; Santos, Raúl D.; Sijbrands, Eric J.G.; Simpson, William G.; Sullivan, David; Сусеков, А. В.; Tomlinson, Brian; Wiegman, Albert; Yamashita, Shizuya; Kastelein, John J.P.

doi:10.1177/2047487314533218

Cited by 140 publications

(237 citation statements)

References 104 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Patients with ATT of 9 mm or more on radiography should be regarded as having tendon xanthomas. 13) International consensus criteria for the clinical diagnosis of FH are lacking, although 3 well-known clinical diagnostic criteria have been proposed; the US MedPed (Make Early Diagnosis To Prevent Early Death) program, [14][15][16] Simon Broome Register Group in the UK, 17,18) and Dutch Lipid Clinic Network. 4,5,19) The Japan Atherosclerosis Society (JAS) proposed simple but high specificity criteria for the diagnosis of heterozygous FH in 2012.…”

Section: Prevalence Of Heterozygous Fh In Acsmentioning

confidence: 99%

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

et al. 2017

View full text Add to dashboard Cite

SummaryHeterozygous familial hypercholesterolemia (FH) represents a strong risk for development of premature coronary artery disease (CAD). However, the majority of patients with FH are undiagnosed and the prevalence likely represents an underestimate in most countries. In Japan, the possible contribution of FH to the development of CAD may be higher because of the low incidence of CAD among the general population. We estimated the prevalence of heterozygous FH by measuring Achilles tendon thickness (ATT) in patients with acute coronary syndrome (ACS).A total of 359 patients suffering from ACS were enrolled in this multicenter registration study. Heterozygous FH was defined according to the diagnostic criteria proposed by the Japan Atherosclerosis Society. After excluding 63 patients because of missing ATT data or plasma triglyceride levels that were 4.5 mmol/L or more, 296 patients were eligible for inclusion in the study. The number of patients with ATT of 9 mm or more was 53 (17.9%). They were significantly younger and had significantly higher LDL cholesterol levels than patients with an ATT less than 9 mm. The prevalence of heterozygous FH was 5.7% (1/17.5) and more prominent in younger patients who were less than 60 years old (7.8%). In patients with ATT of 9 mm or more, approximately 1 in 3.5 fulfilled the criteria for heterozygous FH.We demonstrated the usefulness of measuring ATT by radiography and the high prevalence of heterozygous FH in patients with ACS in Japan, especially in younger patients who were less than 60 years old. (Int Heart J 2017; 58: 88-94)

show abstract

Section: Prevalence Of Heterozygous Fh In Acsmentioning

confidence: 99%

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Los esteroles vegetales no suplen el tratamiento farmacológico adecuadamente prescrito que junto con los cambios nutricionales no debe ser interrumpido. -En adultos y niños (> 6 años) con hipercolesterolemia familiar, como complemento del estilo de vida saludable y el tratamiento farmacológico que requieren estos pacientes (26). No se recomienda el uso de alimentos enriquecidos con esteroles vegetales para niños menores de 6 años (27).…”

Section: Utilidad En La Práctica Clínica ¿Cuándo Podemos Recomendar unclassified

Utilidad de los esteroles vegetales en el tratamiento de la hipercolesterolemia

Fuster¹

2017

Nutr Hosp

View full text Add to dashboard Cite

A consumption of 2 grams per day of plant sterols produces an inhibition of intestinal absorption of cholesterol and reduces the plasma concentration of c-LDL (cholesterol associated with low-density lipoprotein) by around 10%, which has determined its incorporation into different food products like margarines or dairy. The plant sterols develop their action in the intestine, where they reduce the absorption of cholesterol increasing their elimination fecal. In clinical practice, the use of functional foods with plant sterols at the recommended doses can be considered as a complement to lifestyle modifications, in individuals with hypercholesterolemia and low cardiovascular risk but who do not require hypocholesterolemic pharmacological treatment, and also in those patients receiving pharmacological treatment with lipid-lowering drugs and who do not get the therapeutic goals of c-LDL. The hypocholesterolemic effect of plant sterols is additive to that achieved with changes in lifestyle and/or other lipid-lowering agents. Coadministration with statins generates a hypocholesterolemic effect usually greater than that obtained when the statin dose is doubled.Utilidad de los esteroles vegetales en el tratamiento de la hipercolesterolemia ResumenUn consumo de 2 gramos diarios de esteroles vegetales produce una inhibición de la absorción intestinal de colesterol y reduce la concentración plasmática de c-LDL (colesterol asociado a lipoproteínas de baja densidad) alrededor de un 10%, lo que ha determinado su incorporación a diferentes productos alimenticios como margarinas o lácteos. Los esteroles vegetales desarrollan su acción en el intestino, donde dificultan la absorción del colesterol aumentando su eliminación a través de las heces. En la práctica clínica, la utilización de alimentos funcionales con esteroles vegetales a las dosis recomendadas se puede considerar como complemento de las modificaciones del estilo de vida, en individuos con hipercolesterolemia y riesgo cardiovascular global bajo, pero que no precisen tratamiento farmacológico hipocolesterolemiante, y también en aquellos pacientes que reciben tratamiento farmacológico con hipolipemiantes y que no alcanzan los objetivos terapéuticos de c-LDL. El efecto hipocolesterolemiante de los esteroles vegetales es aditivo al alcanzado con los cambios del estilo de vida y/o con otros hipolipemiantes. La coadministración con estatinas genera un efecto hipocolesterolemiante habitualmente superior al obtenido cuando se dobla la dosis de estatina.

show abstract

“…However, FH remains underdiagnosed and undertreated in most countries 1) . Recent guidelines and consensus statements highlight the need for early identification of FH and improving the awareness and management of this condition 1,8,11,13,14) . The prevalence of FH in the Chinese populations appears to be comparable to that in Western countries 10) .…”

Section: Clinical Diagnosis Of Familial Hypercholesterolemiamentioning

confidence: 99%